Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.301NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.36.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.36.7NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.269NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.269NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.234NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.234NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
Z.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Z.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.34.2 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.34.2 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.50NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.50NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.60NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.60NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.52NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.52NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-21820.8US
W.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
W.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
V.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
V.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.149NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.149NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.413NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-15625.1US
B.1.1.413NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.258.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.258.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.9.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.9.5NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.107NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.107NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.2.45NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.2.45NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
GP.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
GP.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FL.4.9NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.4.9NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBQNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBQNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.5.6.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.6.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
CR.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
CR.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
BA.2.86.4NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.86.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XDFNUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XDFNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.575.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used